Normally, an offtake contract is signed first and then project funding follows. However, in this case the reverse has occurred. The Export Credit Agency (ECA) of Britain, the UK Export Finance (UKEF) has provided a non-binding Expression of Interest (EOI) to provide or underwrite up to 70% of the finance for developing Lake’s flagship Kachi Project located in Argentina’s Catamarca Province.
DOWNLOAD RESEARCH REPORT
Blackspur Acquisition is Transformative
Calima is an Australian listed exploration and production (E&P) company, and a Canadian oil and gas pure play. Its assets include a large-scale liquids rich gas play in the Montney fairway in British Columbia, a well-established oil and gas producing region with a supportive energy production policy.
On April 30, 2021, Calima completed the acquisition of Blackspur Oil. Blackspur was caught out in a poor oil environment while laden with a heavy debt burden and Calima was able to capitalise on the opportunity.
DOWNLOAD RESEARCH REPORT
Sustainable sulphate of potash projects to help secure global food production
TMG is developing a brine hosted Indicated and Inferred Resource of 14.3Mt drainable SOP at a high grade of 10.4 kg/m3 SOP equivalent at the potential world class Lake Throssell project. This is a large, scalable deposit able to support a sustainable multi-decade WA production hub to meet growing global demand for SOP.
DOWNLOAD RESEARCH REPORT
Phillips 66 to acquire 16% in NVX – 12-month target price rises 7% through project de-risking
Phillips 66 (PSX) has entered into an agreement with NVX to acquire 77.9m new shares for US$150m (A$203m). PSX is the worlds largest producer of speciality petroleum coke a precursor for battery grade synthetic graphite anode materials found with an Enterprise Value of US$47.5Bn and assets of US$57Bn.
DOWNLOAD RESEARCH REPORT
FDA Feedback as Good As It Gets
Antisense Therapeutics has received formal written feedback from the US Food and Drug Administration (FDA) on its development plans for ATL1102 for non-ambulant patients with Duchenne muscular dystrophy (DMD). In a phase II trial, ATL1102 performed extremely well. The regulatory path for a disease like DMD can be simplified and shortened. To achieve this outcome, though, determining the requirements of regulators is paramount.
DOWNLOAD RESEARCH REPORT
Margins rising on pricing, volumes and management control
After a difficult period late in 2020 that resulted in a worse-than-expected half-year loss, junior thermal coal producer TerraCom has returned to profitability at the EBITDA level so far in 2021, and has positioned itself to reap the benefit of improved coal prices.
DOWNLOAD RESEARCH REPORT
Market leading lifelong learning platform technology company in Australia and SE Asia
PayGroup (PYG) delivers multi-country BPO services and cloud SaaS HCM solutions, assisting companies to manage employees in multiple, complex jurisdictions. The company has many growth opportunities, including new clients, new jurisdictions, new products, partner expansion, and new revenue sources. PYG’s scalable business model allows operating leverage and with savings from in-housing third party technology, support margin expansion.
DOWNLOAD RESEARCH REPORT
Market leading lifelong learning platform technology company in Australia and SE Asia
OpenLearning (OLL) is a higher education technology company that operates a scalable online learning platform through a software-as-a-service (SaaS) business model and provides a global marketplace of high quality courses for learners of all levels. Its primary customers are education providers based in Australia and South-East Asia (primarily Malaysia). OLL started operations in Australia in 2012 and expanded to Malaysia in 2015, Singapore in 2018, and recently also Indonesia.
DOWNLOAD RESEARCH REPORT
Efti a highly sought after compound for mono & combo Cancer treatment
Immutep (IMM.AX) is one of the most promising drug developers listed on the ASX. A core competency is its unsurpassed understanding of the biology of the lymphocyte activation gene-3 (LAG-3) and the development of therapeutics based on that knowledge. In this report, we take a deep-dive into Immutep’s project pipeline. We look at major factors in oncology drug development and the broader market and how Immutep are likely to support the value of its lead asset, eftilagimod alpha (efti), currently in mid-late-stage clinical trials. Finally, we look at the company’s intellectual property and management, the latter being often overlooked by investors.
DOWNLOAD RESEARCH REPORT
Do Two A+ Deals Foreshadow THE DEAL?
Licensing deals are the life blood of small pharmaceutical companies, representing their exit from the development of a molecule, often in a staged manner, and a coalescing of the value they have added to a compound. Kazia Therapeutics has done two licensing deals in the space of a month, something unique for an Australian company. In this report, we look at those deals, assess their quality and look at other takeaways they provide.
